Nexalin Technology, Inc. Common Stock (NXL)
Publicly reported company facts and saved market data for Nexalin Technology, Inc. Common Stock (NXL), with sources and as-of times. Saved data is not a live quote.
Company profile
Nexalin designs and develops innovative neurostimulation products to uniquely help combat the ongoing global mental health epidemic. Nexalin's medical devices are non-invasive and undetectable to the human body. Nexalin products are developed to provide relief to those afflicted with mental health issues using frequency based bioelectronic medical technology. Nexalin believes its neurostimulation medical devices can penetrate structures deep in the mid-brain that are associated with mental health disorders. Nexalin believes the deeper-penetrating waveform in its next-generation devices supports enhanced patient response with a favorable tolerability profile. The Nexalin Gen-2 15 milliamp neurostimulation device has been approved in China, Brazil, Oman and Israel. Additional information about the Company is available at: https://nexalin.com/.
Company facts
- Sector
- Health Care
- Industry
- Electromedical & Electrotherapeutic Apparatus
- Market cap
- $2.8M
- Incorporated in
- United States
- Company website
- www.nexalin.com
- Exchange
- NASDAQ
FennEdge notes
Sessions where NXL appeared in the daily small-cap recap, newest first: opening gap, day change and the SEC filing or halt stored by the close. Facts with source links.
Saved quote
Saved snapshot, not a real-time quote. Check the market time before relying on it.
- Last reported price
- $2.47
- Reported change
- -6.44%
- Reported volume
- 42,676
- Latest market time
Short interest
- Reported short interest
- 12,497 shares
- Settlement date
- Source
- Nasdaq
Exchange-published short interest for the stated settlement date, not a live short position.
Research this company
FennEdge organizes SEC filings and reported market data. Sign in for additional research and your private trading context.
Sign in to continue